Vancomycin plus gentamicin and cotrimoxazole for prevention of infections in neutropenic cancer patients (a comparative, placebo-controlled pilot study).
D000328:Adult; D000380:Agranulocytosis / Q000150:complications*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005243:Feces / Q000382:microbiology; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000150:complications*; D010865:Pilot Projects; D011897:Random Allocation; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014640:Vancomycin / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D004338:Drug Combinations; D005839:Gentamicins; D014640:Vancomycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole